Merck gains big-time on Schering deal

Investors blew kisses at Merck last week. Apparently they were giddy over the Schering-Plough deal: Merck stock gained 23 percent over Thursday and Friday, its biggest two-day gain ever, closing Friday at $27.07. And that kind of gain isn't peanuts, dollarwise. As Dow Jones points out, the two-day rally added more than $10.8 billion to Merck's market cap.

Some good-news triggers helped: The Lancet published data favorable to Schering's anticlotting drug candidate TRA. And in a Friday note to clients, Sanford Bernstein analyst Tim Anderson upgraded Merck to outperform, calling the company a "best-in-class grower." Anderson's new price target for Merck shares is $30.

And Credit Suisse's Catherine Arnold predicted Friday that the combined company would be able to retain its rights to Remicade and a follow-up drug, despite partner Johnson & Johnson's silence on the deal. J&J could attempt to nab full rights to the lucrative med, and some analysts have even theorized that J&J might make a rival bid for Schering.

Meanwhile, Schering agreed to pay $165 million to settle an old shareholder lawsuit that accused the drugmaker of failing to disclose manufacturing problems in 2000-2001. Schering denies wrongdoing. A settlement hearing is scheduled for June 1.

- read the Dow Jones story
- see the settlement news in Forbes

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.